The Efficacy and Safety of High-Dose Cholecalciferol Therapy in Hemodialysis Patients
Tarasewicz A, Komorniczak M, Zakrzewska A, Biedunkiewicz B, Małgorzewicz S, Jankowska M, Jasiulewicz K, Płonka N, Dąbrowska M, Dębska-Ślizień A, Tylicki L
Biomedicines · 3 citas
Cómo se estudió
- Diseño
- Estudio de cohortes (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2024-02-06 · Biomedicines · vol. 12 · número 2 · pág. 377
- Editorial
- Multidisciplinary Digital Publishing Institute
- Citado
- 3 citas · más que el 67% de estudios similares · 0.7× el promedio de su campo
- Referencias
- 33 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Parathyroid Disorders and Treatments · Vitamin D Research Studies · Pharmacological Effects and Toxicity Studies
- Palabras clave
- Cholecalciferol, Medicine, Vitamin D and neurology, Hemodialysis, vitamin D deficiency, Internal medicine, Population, Gastroenterology, Dialysis
11 autores
- Agnieszka Tarasewicz🇵🇱 · autor de correspondenciaGdańsk Medical University
- Michał Komorniczak🇵🇱Gdańsk Medical University
- Agnieszka P. Zakrzewska🇵🇱Gdańsk Medical University
- Bogdan Biedunkiewicz🇵🇱Gdańsk Medical University
- Sylwia Małgorzewicz🇵🇱Gdańsk Medical University
- Magdalena Jankowska🇵🇱Gdańsk Medical University
- Katarzyna Jasiulewicz🇵🇱Gdańsk Medical University
- Natalia Płonka🇵🇱Gdańsk Medical University
- Malgorzata Ewa Dabrowska
- Alicja M Dębska-Ślizień🇵🇱Gdańsk Medical University
- Leszek Tylicki🇵🇱 · autor de correspondenciaGdańsk Medical University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Vitamin D deficiency and insufficiency are highly prevalent in CKD, affecting over 80% of hemodialysis (HD) patients and requiring therapeutic intervention. Nephrological societies suggest the administration of cholecalciferol according to the guidelines for the general population. The aim of the observational study was to evaluate the efficacy and safety of the therapy with a high dose of cholecalciferol in HD patients with 25(OH)D deficiency and insufficiency to reach the target serum 25(OH)D level > 30 ng/mL. A total of 22 patients (16 M), with an average age of 72.5 ± 13.03 years and 25(OH)D concentration of 13.05 (9.00-17.90) ng/mL, were administered cholecalciferol at a therapeutic dose of 70,000 IU/week (20,000 IU + 20,000 IU + 30,000 IU, immediately after each dialysis session). All patients achieved the target value > 30 ng/mL, with a mean time of 2.86 ± 1.87 weeks. In the first week, the target level of 25(OH)D (100%) was reached by 2 patients (9.09%), in the second week by 15 patients (68.18%), in the fourth week by 18 patients (81.18%), and in the ninth week by all 22 patients (100%). A significant increase in 1,25(OH)2D levels was observed during the study. However, only 2 patients (9.09%) achieved a concentration of 1,25(OH)2D above 25 ng/mL-the lower limit of the reference range. The intact PTH concentrations remained unchanged during the observation period. No episodes of hypercalcemia were detected, and one new episode of hyperphosphatemia was observed. In conclusion, our study showed that the administration of a high-therapeutic dose of cholecalciferol allowed for a quick, effective, and safe leveling of 25(OH)D concentration in HD patients.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.